Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study

Conclusion
Based on clinical and health-economic evidence from the PLATO study, treating ACS patients with ticagrelor for 12 months is associated with a cost per QALY below generally accepted thresholds for cost-effectiveness.
ClinicalTrials.gov Identifier: NCT00391872.

Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Nikolic, E., Janzon, M., Hauch, O., Wallentin, L., Henriksson, M., for the PLATO Health Economic Substudy Group Tags: Coronary artery disease Source Type: research